Tirzepatide (20 Mg)

Tirzepatide simultaneously activates GLP-1 and GIP receptors, producing complementary and synergistic metabolic effects:

  • Enhances glucose-dependent insulin secretion   • Suppresses glucagon release, reducing hepatic glucose output   • Slows gastric emptying, promoting prolonged satiety   • Reduces appetite and caloric intake via central nervous system pathways   • Improves insulin sensitivity, particularly through GIP receptor activity The dual-agonist profile allows tirzepatide to achieve greater metabolic efficiency than GLP-1–only therapies.

• Class: Dual GIP / GLP-1 receptor agonist

•   Molecule type: Synthetic peptide

•   Action profile: Central appetite regulation + peripheral glucose control

•   Duration: Long-acting, enabling sustained receptor activation

Research and clinical data demonstrate that tirzepatide produces:   • Significant body-weight reduction   • Marked improvement in glycemic markers (HbA1c, fasting glucose)   • Reduced insulin resistance   • Improved lipid and cardiometabolic parameters These effects position tirzepatide as one of the most potent metabolic peptides currently developed.